Clinical Trial Update: A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 randomized study evaluated three different gemcitabine-based first-line combinations for non-small cell lung cancer, reporting feasibility and activit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED